Oryzon Secures U.S. Patent for AML Drug Combination Therapy — Oryzon Genomics, S.A.

Event summary

Oryzon received a Notice of Allowance from the USPTO for a patent covering iadademstat combined with gilteritinib for treating myeloid cancers, including AML.
The patent is expected to expire in 2042, with additional patent applications pending in other jurisdictions.
Iadademstat in combination with gilteritinib achieved a 67% composite complete remission (CRc) rate in heavily pretreated FLT3-mutated relapsed/refractory AML patients.
Oryzon has seven ongoing oncology clinical trials, including the Phase Ib FRIDA and ALICE-2 studies, with updated positive clinical data presented at EHA 2026.

The big picture

Oryzon's patent allowance strengthens its position in the competitive AML treatment landscape, particularly as it seeks to differentiate iadademstat combinations from existing therapies. The company's focus on epigenetics and personalized medicine aligns with broader industry trends toward targeted cancer treatments. The upcoming data from ongoing trials will be pivotal in determining the commercial potential of iadademstat.

What we're watching

Patent Protection: The long-term intellectual property protection for iadademstat combinations will be critical for Oryzon's competitive positioning in the AML treatment market.
Clinical Trial Outcomes: The pace at which additional, more mature data from the FRIDA and ALICE-2 studies are released will influence investor confidence and potential regulatory approvals.
Market Competition: Whether Oryzon can sustain the favorable safety and efficacy profiles of iadademstat combinations against emerging therapies in the AML space.